title: [Preoperative concurrent chemoradiotherapy with intra-arterial infusion of pirarubicin and continuous intravenous instillation of 5-fluorouracil for resectable advanced head and neck squamous cell carcinoma].
abstract: Eight cases (4 of the maxillary sinus, 3 of the tongue, and one of the oral floor) of resectable advanced head and neck squamous cell carcinoma were treated preoperatively by means of concurrent chemoradiotherapy with combination of pirarubicin (THP), 5-fluorouracil (5-FU), and radiation between March 2001 and April 2002. THP (5 mg/day) was infused into the maxillary or lingual artery through a catheter placed in the superficial temporal artery one hour before radiotherapy on days 1-5 and 8-12. In addition, continuous intravenous instillation of 5-FU (150 mg/m2/day) was performed on days 1-5, 8-12, 15-19, and 22-26 in accordance with the radiotherapy schedule (2 Gy/day). The total doses of THP, 5-FU, and radiation were 50 mg, 3,000 mg/m2 and 40 Gy, respectively. Five out of 8 patients showed a complete response and the remaining 3 a partial response, for a 100% response rate. In particular, all 4 cases of tongue and oral floor carcinoma showed a complete response. All patients were able to undergo this series of therapy as scheduled without any severe adverse effects. We conclude that this concurrent chemoradiotherapy is feasible for preoperative therapy in view of the good locoregional control rate and the negligible adverse effects.
authors.affiliation: Dept. of Otolaryngology, Osaka City University Graduate School of Medicine.
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Iguchi
authors.forename: Makoto
authors.initials: M
authors.lastname: Kusuki
authors.forename: Aki
authors.initials: A
authors.lastname: Nakamura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nishiura
authors.forename: Akimori
authors.initials: A
authors.lastname: Kanazawa
authors.forename: Hideo
authors.initials: H
authors.lastname: Yamane
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous / Q000379:methods; D008297:Male; D008875:Middle Aged; D019990:Perioperative Care
chemical_list: D004317:Doxorubicin; C027260:pirarubicin; D005472:Fluorouracil